RobertoCArduinoMD

Infectious Disease • Houston, TX

Professor, Internal Medicine, University of Texas Medical School, Houston

Join to view full profile

Dr. Arduino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arduino's full profile

Already have an account?

Office
2015 Thomas St
Houston, TX 77009
Phone+1 713-873-4000

Fax+1 713-500-0610

Education & Training

University of Texas Health Science Center at HoustonFellowship, Infectious Disease, 1990 - 1994
University of Buenos AiresClass of 1982

Certifications & Licensure

TX State Medical License 1994 - 2025

Clinical Trials

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials Start of enrollment: 2000 Jan 01
Completed
"The Once A Day Protease Inhibitor Regimens" Start of enrollment: 2004 May 01
Completed
Phase 4
Collection of Blood Samples From SMART Study Participants for Future Genetic Studies
Completed
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals Start of enrollment: 2010 Dec 01
Completed
Phase 1
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
COMPLETED
PHASE2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
PRO 140 for Human Immunodeficiency Virus Infection Start of enrollment: 2014 Sep 01
Withdrawn
Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
Completed
Phase 1, Phase 2
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) Start of enrollment: 2017 Mar 14
COMPLETED
PHASE3
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Start of enrollment: 2023 May 30
COMPLETED
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Pulmonary disease caused byin Colombia.
Darío Sebastián López-Delgado, Gabriel Alonso Rodríguez-Caicedo, Diego Fernando Taramuel-Gómez, Peter Houck, Martha Isabel Murcia-Aranguren
New Microbes and New Infections. 2025-04-01
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.
Nia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, Rodney Dawson, Yoninah Cramer
Pharmacogenetics and Genomics. 2025-02-12
4 citations
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.
Boris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, Malika Aid, Kathryn E Stephenson
Nature Medicine. 2024-12-01

Press Mentions

Study Shows Counseling via Cell Phone Helps Smokers with HIV/AIDS QuitFebruary 10th, 2016

RobertoCArduinoMD

Dr. Arduino is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.